MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
XNCR stock logo

XNCR

Xencor, Inc.

$12.81
0.28
 (2.23%)
Exchange:  NASDAQ
Market Cap:  939.467M
Shares Outstanding:  16.693M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Bassil I. Dahiyat
Full Time Employees:  250
Address: 
111 West Lemon Avenue
Pasadena
CA
91016
US
Website:  https://www.xencor.com
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer’s disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2024/02/28 — 4 quarter 2023

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue174,615110,493125,576
Gross Profit174,615110,493115,064
EBITDA-101,959-186,173-46,980
Operating Income-132,362-178,408-177,502
Net Income-133,133-232,618-91,923

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets952,692951,945875,495
Total Liabilities283,559277,919239,908
Total Stockholders Equity668,796677,611635,587
Total Debt83,434231,95367,998
Cash and Cash Equivalents53,79040,87554,073

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow85,111-202,188-135,117
Capital Expenditure-21,251-6,097-3,150
Free Cash Flow63,860-208,285-138,267
Net Income-126,087-236,540-91,923
Net Change in Cash228-12,90813,100

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)105,463.174Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,070,842.008Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)520,219.857Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-408,643.167Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-40,245.718Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-198,520.686Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)-4,535.690Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)69.589Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)-1,908.981Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)37,887.556Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)384,699.092Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)186,888.546Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)-0.030Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)-0.060Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)4Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)3Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
110.493M  ?P/S
 (TTM)
: 
7.63
?Net Income
 (TTM)
: 
-232618000  ?P/E
 (TTM)
: 
-10.55
?Enterprise Value
 (TTM)
: 
1.091B  ?EV/FCF
 (TTM)
: 
-7.89
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.15  ?ROIC
 (TTM)
: 
-0.21
?Net Debt
 (TTM)
: 
-265822000  ?Debt/Equity
 (TTM)
: 
0.3
?P/B
 (TTM)
: 
1.53  ?Current Ratio
 (TTM)
: 
6.25

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate XNCR Intrinsic Value

Common questions about XNCR valuation

Is Xencor, Inc. (XNCR) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Xencor, Inc. (XNCR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is XNCR a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether XNCR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is XNCR’s P/E ratio?

You can see XNCR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for XNCR?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is XNCR a good long-term investment?

Whether XNCR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

XNCR

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

2.23
MARKETSnap

Trading Metrics:

Open: 12.49   Previous Close: 12.53
Day Low: 12.2   Day High: 12.83
Year Low: 6.92   Year High: 18.69
Price Avg 50: 12.04   Price Avg 200: 11.84
Volume: 582098   Average Volume: 767495

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
11-03-2026 13:32
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of “Moderate Buy” from Analysts
10-03-2026 02:26
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of “Moderate Buy” from Analysts
Xencor (NASDAQ:XNCR) Shares Gap Down  Following Insider Selling
06-03-2026 01:52
Xencor (NASDAQ:XNCR) Shares Gap Down Following Insider Selling
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
25-02-2026 21:06
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
19-01-2026 02:26
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942
01-01-2026 07:14
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read